Cheryl H. Arrowsmith is a Canadian structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology[1] includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

Cheryl Arrowsmith
NationalityCanadian
Alma materUniversity of Toronto
Scientific career
FieldsStructural biology
InstitutionsStructural Genomics Consortium

She received her Ph.D. in chemistry at the University of Toronto in 1987 and post-doctoral training at Stanford University working with Oleg Jardetzky. One of her areas of interest is the tumour suppressor p53 and related proteins.[2]

Her current research is to determine the 3-dimensional structures of human proteins of therapeutic relevance by structural proteomics.[3] She has made significant contributions to epigenetic signaling in the context of drug discovery.[4]

Arrowsmith was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2015.[5] She was also named as one of the Clarivate Highly Cited Researchers in 2023.[6]

References

edit
  1. ^ "Cheryl H. Arrowsmith". uhnresearch.ca. Retrieved December 27, 2017.
  2. ^ "Cheryl Arrowsmith". utoronto.ca. Retrieved December 27, 2017.
  3. ^ Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. Bibcode:2006Sci...311..347C. doi:10.1126/science.1121018. PMID 16424331. S2CID 800902.
  4. ^ Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11, 384–400 (2012)
  5. ^ "Arrowsmith named AAAS Fellow". utoronto.ca. Retrieved December 27, 2017.
  6. ^ "Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List". Clarivate. 2023-11-15. Retrieved 2024-01-03.